Fibrinogen measurement to assess the risk of arterial thrombosis in individual patients: Yes

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 4, 2005, Pages 632-634

  Meade, Tom W ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; C REACTIVE PROTEIN; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GEMFIBROZIL;

ARTERY THROMBOSIS; ATHEROMA; BLOOD VISCOSITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG MECHANISM; DRUG TOLERANCE; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; SMOKING; THROMBOCYTE ACTIVATION; ARTERY; ARTICLE; BIOSYNTHESIS; BLOOD; BLOOD CLOTTING TEST; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; METHODOLOGY; PATHOLOGY; RISK; RISK FACTOR; THROMBOCYTE AGGREGATION;

ARTERIES; BLOOD COAGULATION TESTS; CORONARY DISEASE; CORONARY THROMBOSIS; FIBRINOGEN; HUMANS; PLATELET AGGREGATION; RISK; RISK FACTORS;

EID: 23044513950     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01255.x     Document Type: Short Survey

References (27)

1. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-82.
2. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
3. Baker IA, Pickering J, Elwood PC, Bayer A, Ebrahim S. Fibrinogen, viscosity and white blood cell count predict myocardial, but not cerebral infarction: evidence from the Caerphilly and Speedwell cohort. Thromb Haemost 2002; 87: 421-5.
4. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
5. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-5.
6. Smith FB, Rumley A, Lee AJ, Leng GC, Fowkes FG, Lowe GD. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998; 100: 758-63.
7. Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. Arterioscler Thromb Vasc Biol 1999; 19: 1776-83.
8. Banerjee AK, Pearson J, Gilliland EL, Goss D, Lewis JD, Stirling Y, Meade TW. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost 1992; 68: 261-3.
9. Wiseman S, Kenchington G, Dain R, Marshall CE, McCollum CN, Greenhalgh RM, Powell JT. Influence of smoking and plasma factors on patency of femoropopliteal vein grafts. BMJ 1989; 299: 643-6.
10. Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 1995, 31-8.
11. Morris JN. Recent history of coronary disease. Lancet 1951; 1: 1-7.
12. Chandler AB, Chapman I, Erhardt LR, Roberts WC, Schwartz CJ, Sinapius D, Spain DM, Sherry S, Ness PM, Simon TL. Coronary thrombosis in myocardial infarction. Report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction. Am J Cardiol 1974; 34: 823-33.
13. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310: 1137-40.
14. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Circulation 1985; 71: 699-708.
15. DeWood MA, Stifter WF, Simpson CS, Spores J, Eugster GS, Judge TP, Hinnen ML. Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med 1986; 315: 417-23.
16. Law MR, Wald NJ, Morris JK. The performance of blood pressure and other cardiovascular risk factors as screening tests for ischaemic heart disease and stroke. J Med Screen 2004; 11: 3-7.
17. Meade TW. The epidemiology of atheroma, thrombosis and ischaemic heart disease. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis, pp. 1199-227. Edinburgh: Churchill Livingstone, 1994.
18. Youngman LD, Keavney BD, Palmer A, Parish S, Clark S, Danesh J, Delepine M , Lathrop M , Peto R, Collins R. Plasma fibrinogen and fibrinogen genotypes in 4685 cases of myocardial infarction and in 6002 controls: test of causality by 'Mendelian randomisation'. Circulation 2000; 102: 31-2.
19. Keavney B, Palmer A, Parish S, Clark S, Youngman L, Danesh J, McKenzie C, Delepine M, Lathrop M, Peto R, Collins R and the International Studies of Infarct Survival (ISIS) Collaborators. Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk. Int J Epidemiol 2004; 33: 1002-13.
20. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. Public Health Papers, no. 34. Geneva: WHO, 1968.
21. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002; 325: 1139.
22. MacCallum PK, Cooper JA, Rumley A, Lowe GD, Meade TW. Effect of bezafibrate on plasma homocysteine concentration in men with lower extremity arterial disease. J Thromb Haemost 2004; 2: 364-5.
23. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45.
24. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 410-18.
25. Wilkes HC, Meade TW, Barzegar S, Foley AJ, Hughes LO, Bauer KA, Rosenberg RD, Miller GJ. Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemost 1992; 67: 503-6.
26. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001; 85: 265-71.
27. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure, prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.